Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delayed Release Brilacidin in Healthy Volunteers
NCT04240223Phase 1Completed
- Sponsor
- Innovation Pharmaceuticals Inc.
- Start
- Jan 2020
- Primary completion
- Feb 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of brilacidin in ulcerative colitis (UC) (6 arms), sponsored by Innovation Pharmaceuticals Inc. Primary endpoints: Site of release of radiolabel at 14 hours, Time to release of radiolabel at 14 hours and 1 more. Started Jan 2020; status: completed.
02
Drugs
brilacidin
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04240223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04240223.